Appendix S1.

Search strategy for the systematic literature search

For observational studies

# 1 Dermatitis, Atopic/
# 2 atopic dermatitis.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
# 3 Eczema/
# 4 eczema.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
# 5 1 or 2 or 3 or 4
# 6 epidemiologic studies/ or exp case–control studies/ or exp cohort studies/ or exp seroepidemiologic studies/
# 7 (epidem: adj stud:).mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
# 8 6 or 7
# 9 5 and 8
# 10 exp Hypersensitivity, Immediate/
# 11 Allergens/
# 12 Skin Tests/
# 13 Hypersensitivity/
# 14 prick.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
# 15 exp Immunoglobulin E/
# 16 immunoglobulin E.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
# 17 IgE.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
# 18 Genotype/
# 19 Genetic Heterogeneity/
# 20 Hygiene Hypothesis/
# 21 Animals, Domestic/
# 22 Cats/
# 23 Dogs/
# 24 Avoidance Learning/
# 25 Administration, Topical/
# 26 Intermediate Filament Proteins/df, ge [Deficiency, Genetics]

# 27 Therapeutics/mt, ut [Methods, Utilization]
# 28 Pharmaceutical Preparations/ad, de [Administration & Dosage, Drug Effects]
# 29 Adrenal Cortex Hormones/df, ge [Deficiency, Genetics]
# 30 Androstadienes/tu [Drug Therapy, Therapeutic Use]
# 31 Calcineurin/ai [Antagonists & Inhibitors]
# 32 Dermatologic Agents/tu [Therapeutic Use]
# 33 Immunosuppressive Agents/tu [Therapeutic Use]
# 34 Methylprednisolone/aa, tu [Analogs & Derivatives, Therapeutic Use]
# 35 Tacrolimus/tu [Therapeutic Use]
# 36 allerg:.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] (142303)
# 37 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
# 38 9 and 37
# 39 limit 38 to humans
# 40 limit 39 to (english or german)
# 41 limit 41 to abstracts

For RCT

# 1 randomized controlled trial.pt.
# 2 controlled clinical trial.pt.
# 3 randomized.ab.
# 4 randomly.ab.
# 5 placebo.ab.
# 6 trial.ti.
# 7 clinical trials as topic.sh.
# 8 1 or 2 or 3 or 4 or 5 or 6 or 7
# 9 humans.sh.
# 10 exp Animals/
# 11 10 not 9
# 12 8 not 11
# 13 Dermatitis, Atopic/
# 14 atopic dermatitis.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
# 15 13 or 14
# 16 Eczema/
# 17 eczema.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
# 18 16 or 17
# 19 15 or 18
# 20 12 and 19